Skip to main content
Premium Trial:

Request an Annual Quote

Burning Rock Biotech, Abbisko Therapeutics Ink CDx Partnership for ABSK091

NEW YORK – Burning Rock Biotech said on Thursday that it has entered a strategic partnership with Abbisko Therapeutics to develop a companion diagnostic assay for the pharma firm's ABSK091, formerly known as AZD4547.

The CDx assay will be used to detect FGFR genetic alterations in patients with urothelial carcinoma and will serve to advance clinical research and development of ABSK091, a small molecule FGFR inhibitor.

Financial terms of the deal were not disclosed.

"ABSK091 has shown the potential to treat patients with FGFR signaling pathway-dependent tumors in previous studies. Our collaboration with Abbisko is expected to … further advance the standardization of FGFR detection for patients with urothelial carcinoma in China," Xinru Mao, head of Burning Rock's pharmaceutical business development, said in a statement.

Jing Ji, Abbisko's chief medical officer, added that the company has obtained investigational new drug approval from China's National Medical Products Administration for the treatment of patients with urothelial carcinoma and plans to soon initiate Phase Ib/II multicenter clinical trials in China.

"We look forward to working with Burning Rock to accelerate the clinical development and advance this innovative drug into market as early as possible to provide a novel treatment option for patients and doctors," Ji said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.